130 related articles for article (PubMed ID: 28223177)
1. Pneumocystis pneumonia in patients with inflammatory or autoimmune diseases: Usefulness of lymphocyte subtyping.
Li Y; Ghannoum M; Deng C; Gao Y; Zhu H; Yu X; Lavergne V
Int J Infect Dis; 2017 Apr; 57():108-115. PubMed ID: 28223177
[TBL] [Abstract][Full Text] [Related]
2. Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases.
Braga BP; Prieto-González S; Hernández-Rodríguez J
Med Clin (Barc); 2019 Jun; 152(12):502-507. PubMed ID: 30853123
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for prophylaxis of Pneumocystis pneumonia cannot rely solely on CD4-cell count in autoimmune and inflammatory diseases.
Baulier G; Issa N; Gabriel F; Accoceberry I; Camou F; Duffau P
Clin Exp Rheumatol; 2018; 36(3):490-493. PubMed ID: 29533748
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention.
Sowden E; Carmichael AJ
BMC Infect Dis; 2004 Oct; 4():42. PubMed ID: 15488151
[TBL] [Abstract][Full Text] [Related]
5. Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death.
Chen M; Tian X; Qin F; Zhou J; Liu J; Wang M; Xu KF
PLoS One; 2015; 10(9):e0139144. PubMed ID: 26422246
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors of Pneumocystis pneumonia in patients with systemic autoimmune diseases.
Kageyama T; Furuta S; Ikeda K; Kagami SI; Kashiwakuma D; Sugiyama T; Umibe T; Watanabe N; Yamagata M; Nakajima H
PLoS One; 2019; 14(3):e0214324. PubMed ID: 30908547
[TBL] [Abstract][Full Text] [Related]
7. Pneumocystis jirovecii pneumonia in patients with autoimmune disease on high-dose glucocorticoid.
Chew LC; Maceda-Galang LM; Tan YK; Chakraborty B; Thumboo J
J Clin Rheumatol; 2015 Mar; 21(2):72-5. PubMed ID: 25710857
[TBL] [Abstract][Full Text] [Related]
8. Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy.
Lv J; Zhang H; Cui Z; Su T; Zhang Y; Wang H
Nephrol Dial Transplant; 2008 Sep; 23(9):2868-72. PubMed ID: 18463325
[TBL] [Abstract][Full Text] [Related]
9. Pneumocystis carinii pneumonia in patients with connective tissue disease.
Li J; Huang XM; Fang WG; Zeng XJ
J Clin Rheumatol; 2006 Jun; 12(3):114-7. PubMed ID: 16755237
[TBL] [Abstract][Full Text] [Related]
10. Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease.
Ye WL; Tang N; Wen YB; Li H; Li MX; Du B; Li XM
Int Urol Nephrol; 2016 Nov; 48(11):1863-1871. PubMed ID: 27351666
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features and prognosis of pneumocystis pneumonia in patients treated with rituximab for autoimmune diseases].
Zhang W; Wang X; Hu Y; Huang JJ; Cheng Y; Jin Z; Wang GF
Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(8):614-618. PubMed ID: 32164117
[No Abstract] [Full Text] [Related]
12. Combine use of glucocorticoid with other immunosuppressants is a risk factor for Pneumocystis jirovecii pneumonia in autoimmune inflammatory disease patients: a meta-analysis.
Wang H; Shui L; Chen Y
Clin Rheumatol; 2023 Jan; 42(1):269-276. PubMed ID: 36149536
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of Pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy.
Fritzsche C; Riebold D; Munk-Hartig A; Klammt S; Neeck G; Reisinger E
Scand J Rheumatol; 2012 May; 41(3):208-13. PubMed ID: 22400983
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics of Pneumocystis carinii pneumonia in children with systemic lupus erythematosus].
Tang XY; Li J; Dong F; Song HM
Zhonghua Er Ke Za Zhi; 2013 Dec; 51(12):920-4. PubMed ID: 24495763
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
Obeid KM; Aguilar J; Szpunar S; Sharma M; del Busto R; Al-Katib A; Johnson LB
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):66-9. PubMed ID: 22000698
[TBL] [Abstract][Full Text] [Related]
16. Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions.
Lehman JS; Kalaaji AN
J Am Acad Dermatol; 2010 Nov; 63(5):815-23. PubMed ID: 20643496
[TBL] [Abstract][Full Text] [Related]
17. A case of Pneumocystis jiroveci pneumonia in X-linked agammaglobulinaemia treated with immunosuppressive therapy: a lesson for immunologists.
Sirianni MC; Atzori C; De Santis W; Milito C; Esposito A; Marziali M; Bernardi ML; Cargnel A; Aiuti F
Int Arch Allergy Immunol; 2006; 140(1):82-8. PubMed ID: 16549936
[TBL] [Abstract][Full Text] [Related]
18. Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: A case-control study.
Tadros S; Teichtahl AJ; Ciciriello S; Wicks IP
Semin Arthritis Rheum; 2017 Jun; 46(6):804-809. PubMed ID: 27814896
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?
Wolfe RM; Peacock JE
Curr Rheumatol Rep; 2017 Jun; 19(6):35. PubMed ID: 28488228
[TBL] [Abstract][Full Text] [Related]
20. Development of Pneumocystis carinii pneumonia in patients with immunobullous and connective tissue disease receiving immunosuppressive medications.
Gerhart JL; Kalaaji AN
J Am Acad Dermatol; 2010 Jun; 62(6):957-61. PubMed ID: 19828210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
